Abstract
Ranibizumab (Lucentis) vs Aflibercept (Eyelea) for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in rural clinical practice
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have